CEO of Nabriva Therapeutics Plc (30-Year Financial, Insider Trades) Theodore R Schroeder (insider trades) bought 50,000 shares of NBRV on 08/27/2019 at an average price of $1.79 a share. The total cost of this purchase was $89,500.
Nabriva Therapeutics AG is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics PLC has a market cap of $154.059 million; its shares were traded at around $2.10 . GuruFocus has detected 3 severe warning signs with Nabriva Therapeutics PLC. .
CEO Recent Trades:
- CEO Theodore R Schroeder bought 50,000 shares of NBRV stock on 08/27/2019 at the average price of $1.79. The price of the stock has increased by 17.32% since.
CFO Recent Trades:
- CFO Gary Sender sold 3,390 shares of NBRV stock on 08/21/2019 at the average price of $2.08. The price of the stock has increased by 0.96% since.
Directors and Officers Recent Trades:
- Chief Commercial Officer Francesco Maria Lavino bought 4,800 shares of NBRV stock on 08/22/2019 at the average price of $2.04. The price of the stock has increased by 2.94% since.
- Director Colin Md Broom sold 10,177 shares of NBRV stock on 08/21/2019 at the average price of $2.07. The price of the stock has increased by 1.45% since.
- President & COO Steven P. Gelone sold 8,206 shares of NBRV stock on 08/21/2019 at the average price of $2.08. The price of the stock has increased by 0.96% since.
- Gen Counsel & Corp Secretary Robert Crotty sold 3,797 shares of NBRV stock on 08/21/2019 at the average price of $2.08. The price of the stock has increased by 0.96% since.
- Chief Commercial Officer Francesco Maria Lavino sold 3,797 shares of NBRV stock on 08/21/2019 at the average price of $2.08. The price of the stock has increased by 0.96% since.
For the complete insider trading history of NBRV, click here
.
